Pfizer launches study to track symptoms of COVID-19 and flu in real time
NCT ID NCT05160636
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows about 1,000 adults in the U.S. who test positive for COVID-19 or influenza. Participants fill out surveys about their symptoms and quality of life over six months. The goal is to understand how these illnesses affect daily activities and whether COVID-19 vaccination changes the experience.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- COVID-19 Vaccine (Pfizer-BioNTech)
- What this could lead to
- If successful, this study could help researchers better understand how COVID-19 and flu affect daily life and whether vaccination reduces symptom severity.
- What could go wrong
- This is an observational survey study, not a controlled trial. Results may not prove cause and effect, and rely on self-reported data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONAVIRUS DISEASE 2019 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?